Patient resources
This website is only intended for UK patients who have been prescribed TAGRISSO® (osimertinib)
Patient resources
View our resources designed to support you on your osimertinib treatment plan.
GB-61987 I DOP: December 2024
This website is only intended for UK patients who have been prescribed TAGRISSO®(osimertinib), which is indicated after surgery in adults with stage 1B-3A NSCLC with a particular EGFR mutation, and also in locally advanced or metastatic NSCLC with a particular EGFR mutation. It does not replace the Patient Information Leaflet, which you can find in the carton containing your medicine and which you should read alongside this information. If you have any questions about your treatment, talk to your healthcare team or refer to the Patient Information Leaflet.